The treatment is the first approved gene therapy for AADC deficiency, the FDA said. People with this rare disorder have ...
The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...
Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...
This therapy is designed to address the needs of children and adults with aromatic L-amino acid decarboxylase (AADC) ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidiâ„¢ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...
Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...
PTC Therapeutics (PTCT) announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever ...
PTC Therapeutics’ gene therapy, Kebilidi to treat AADC deficiency receives US FDA approval: Warren, New Jersey Friday, November 15, 2024, 10:00 Hrs [IST] PTC Therapeutics, Inc., ...
Modifying Treatment for AADC Deficiency in the United States SOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ...
The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...